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Pompe disease (glycogen storage disease type II) is an
autosomal recessive lysosomal storage disorder caused by
a deficiency of the enzyme acid alpha-glucosidase. Enzyme
replacement therapy (ERT) with alglucosidase alfa has
resulted in a clinical benefit in a subset of patients. Cross-
reactive Immunological Material (CRIM)-negative status is
associated with poor prognosis. Patients with CRIM-nega-
tive infantile Pompe disease mount a strong immune
response against alglucosidase alfa ERT, resulting in a clin-
ical decline and death despite therapy. Most develop high
sustained antibody titers. Based on our clinical and labora-
tory experience, about 40 percent of patients with infantile
Pompe disease develop HSAT. Early identification of
patients at risk is needed to allow for treatment interven-
tion with immune tolerance induction (ITI) protocols.
These protocols have included the use of agents such as
rituximab, methotrexate, IVIG, and agents that target the
plasma cells. Different treatment approaches are needed
for patients with Pompe disease treated with ITI in the
naïve setting as compared to patients with high sustained
antibody titers. Without ITI, the CRIM-negative patients
do poorly on ERT alone. We will present a successful glo-
bal experience in 15 cases and discuss the safety, efficacy
and feasibility of a clinical algorithm developed at our
institution to identify CRIM-negative status and allow
timely initiation of ERT and ITI in this vulnerable popula-
tion. Our data show that the clinical algorithm of rapidly
diagnosing and initiating ITI coincident with the start of
ERT in CRIM-negative patients is feasible and can be
achieved in a timely manner.
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